Primary familial brain calcification (PFBC) is a genetic neurodegenerative condition characterized by calcium deposition in the basal ganglia and other brain regions usually presenting with a combination of movement disorders, migraine, psychiatric, and cognitive impairment. The exact prevalence of PFBC is unknown, but population-based genomic analysis indicates that it is underestimated and underdiagnosed,^[@R1]^ with a molecular diagnosis achieved in only up to 50% of PFBC cases.^[@R2]^ The pathogenesis of PFBC involves calcium and phosphate homeostasis via mutations in *SLC20A2* (OMIM: 158378) and *XPR1* (OMIM: 605237) and endothelial integrity and function affecting the blood-brain barrier via mutations in *PDGFB* (OMIM: 190040) and *PDGFRB* (OMIM: 173410). Among these, mutations in *SLC20A2* account for approximately 45% of all autosomal dominant and de novo reported familial cases from diverse ethnicities.^[@R3]^ However, a large proportion of autosomal recessive PFBC remain undiagnosed.^[@R4]^ Recently, biallelic mutations in *MYORG* (OMIM: 618255) have been implicated in the pathogenesis of autosomal recessive PFBC in families of Chinese^[@R5]^ and French^[@R6]^ ethnicity. Here, we report a large multicentric cohort of ethnically diverse patients with biallelic variants in *MYORG* and broaden the phenotypic spectrum related to *MYORG* mutations.

Methods {#s1}
=======

Patients {#s1-1}
--------

Patients with an autosomal recessive or negative family history and confirmed clinical and radiologic diagnosis of PFBC were recruited from multiple centers. Genetic testing was performed on stored blood samples of patients with unidentified etiologies of PFBC. Ethnically, the families were of British, Italian, Irish, Pakistani, and Israeli origin. Secondary causes of brain calcification were excluded in all cases. All cases were negative for other PFBC-related genes (*SLC20A2, PDGFRB, PDGBB,* and *XPR1*) and had comprehensive phenotyping performed by neurogenetics specialists.

In cases with biallelic *MYORG* variants, the results from additional investigations were retrospectively analyzed based on chart review where available: neuroimaging with CT in all reported cases (n = 8), brain MRI (n = 4), dopamine active transporter (DAT) scan (n = 2), and fluorodeoxyglucose-PET (n = 2). Cognitive impairment was assessed by formal psychometry.

Genetic testing {#s1-2}
---------------

DNA was extracted from peripheral blood. Whole-exome sequencing was performed in all families. An Illumina HiSeq4000 instrument (Illumina, San Diego, CA) was used to generate 100 bp paired-end reads. Alignment was performed using BWA ([bio-bwa.sourceforge.net/](http://bio-bwa.sourceforge.net/))^[@R7]^ with GRCH38 as a reference. Variants were called using the GATK^[@R8][@R9][@R11]^ UnifiedGenotyper-based pipeline^[@R8][@R9][@R10]^ workflow. All variants were annotated using ANNOVAR^[@R12]^ and filtered using custom R scripts. Only novel or very rare variants with a minor allele frequency of \<0.01 in the 1000 Genomes Project^[@R13]^ and Genome Aggregation Database (gnomAD)^[@R14]^ or known pathologic mutations were included. Variants were filtered for homozygous, compound heterozygous, highly deleterious, rare mutations segregating with the disease. Except for families 1 and 7, segregation was confirmed in all other families.

For every rare *MYORG* variant identified (ENST00000297625, GenBank transcript ID NM_020702), we determined pathogenicity and novelty. Pathogenicity was assessed using the American College of Medical Genetics and Genomics and the Association for Molecular Pathology recommendations for variant classification.^[@R15]^ Only pathogenic and likely pathogenic variants were included here. All pathogenic and likely pathogenic variants were confirmed with bidirectional Sanger sequencing. Primers are available in table e-1 ([links.lww.com/NXG/A227](http://links.lww.com/NXG/A227)).

Standard protocol approvals, registrations, and patient consents {#s1-3}
----------------------------------------------------------------

The individuals included in this study were recruited along with unaffected family members under ethics-approved research protocols (UCLH: 04/N034) with informed consent.

Data availability {#s1-4}
-----------------

Anonymized data used for this study are available from the corresponding authors on reasonable request. A data access agreement needs to be signed.

Results {#s2}
=======

Genetic spectrum {#s2-1}
----------------

We screened 86 cases from 60 families with PFBC that were negative for pathogenic variants in *SLC20A2, PDGFB, PDGFRB*, and *XPR1* and had a recessive or negative family history. We identified pathogenic and likely pathogenic homozygous and compound heterozygous variants in *MYORG* (ENST00000297625, GenBank transcript ID NM_020702) in 8 cases from 7 families (figure e-1, [links.lww.com/NXG/A227](http://links.lww.com/NXG/A227)). Overall, biallelic *MYORG* mutations accounted for 11.6% (7/60) of PFBC families in our cohort. We identified 12 distinct mutations, of which 4 were novel ([figure 1A](#F1){ref-type="fig"}) and 8 were present in gnomAD with very low allele frequency in the heterozygous state and absent in the homozygous state (table e-2). With the exception of 1 variant (p.Ile656Thr), none of the variants presented here have been previously reported in *MYORG*-related brain calcifications. Apart from copy number variants, all types of mutations have been found in this cohort (1 nonsense, 1 frameshift deletion, 1 insertion, and 9 missense variants). All missense variants were located in conserved and highly conserved amino acid positions ([figure 1B](#F1){ref-type="fig"}). The 12 mutations identified in this study were located throughout the gene with no obvious mutational hotspots. Two mutations were inherited in the homozygous state in the 2 consanguineous families; the 5 nonconsanguineous families presented with compound heterozygous variants.

![Genetic spectrum of *MYORG* mutations\
(A) Schematic representation of *MYORG* with all the mutations identified in our study and those reported to date. The *MYORG* functional domains and their cellular localization are indicated: green, N-terminal sequence (cytoplasmic); gray, helical (transmembrane); orange, glycosidase domain (extracellular). The mutations reported in this cohort are plotted on top of the gene; mutations previously reported are below the gene. (B) Conservation across species for novel missense *MYORG* variants. The variants are marked with red boxes for the corresponding amino acid.](NG2019011999f1){#F1}

Phenotype spectrum {#s2-2}
------------------

In our cohort, *MYORG* mutation carriers presented with a high phenotypic variability. The average age at onset was 59.1 years (median 56.4 years, range 39 years to incidental finding at 87 years). Symptoms at onset varied from parkinsonism (37.5%), ataxia and/or dysarthria (37.5%), and headache (12.5%). Insidious onset with brain calcifications found incidentally was in 12.5% of cases. [Table 1](#T1){ref-type="table"} and table e-3 ([links.lww.com/NXG/A227](http://links.lww.com/NXG/A227)) present clinical details of all *MYORG*-related cases included in this study.

###### 

Phenotype description of all *MYORG* mutations reported in this study

![](NG2019011999t1)

An initial progressive parkinsonism associated with supranuclear gaze palsy phenotype was identified in 1/3 of cases at disease onset. Case 1 presented at the initial clinical examination age 40 years with profound facial hypomimia with a staring expression, reduced up and down gaze, associated with profound bilateral bradykinesia, rigidity, reduced arm swings, and a combination of ataxia and freezing. She had poor response to levodopa. Case 5 presented at age 56 years with asymmetric parkinsonism and supranuclear gaze palsy with poor response to levodopa. Progressive deterioration of motor function, dysarthria, dysphagia, and gait ataxia became evident over the following years. Case 8 presented at age 62 years with parkinsonism, frequent falls, staring gaze with vertical gaze palsy that progressed over 16 years along with gait ataxia, cognitive decline, urinary incontinence, and pyramidal signs. All cases presenting with parkinsonism and supranuclear gaze palsy had associated cognitive impairment characterized by executive dysfunction, poor verbal fluency, and concrete verbal reasoning with low scores on Mini-Mental State Examination (MMSE). Two of the 3 patients had a reduced tracer uptake on DAT scan consistent with symmetrical, bilateral marked loss of presynaptic dopaminergic neurons (particularly in the putamen).

A cerebellar-bulbar syndrome of variable severity was present in all our cases ranging from very mild (case 4) to moderate dysarthria and dysphagia affecting mainly speech and swallowing (cases 2, 6, and 7). Severe gait and limb ataxia was present in 3/8 of cases (cases 1, 3, and 5). Parkinsonism was detectable in 7 of 8 cases, often associated with other features including supranuclear gaze palsy, early frequent falls, early cognitive decline, and lack of response to levodopa.

One associated extrapyramidal sign in *MYORG*-related disease was limb dystonia. This was clinically presenting as dystonic posturing in the upper limb precipitated by walking. A third of our patients had bilateral pyramidal signs in the lower limbs. Other associated clinical features were headache (2 cases), urinary incontinence (2 cases), and cramps in the lower limbs (1 case).

Neuropsychiatric evaluation revealed 2 cases with depression. Cognitive assessment showed impaired cognitive function in 62.5% of cases, with different degrees of severity. *MYORG* patients showed reduced verbal fluency and poor verbal reasoning in the first year of disease (cases 1 and 3), mild memory impairment (case 2, MMSE 27/30) with progression over the following years (case 7, Montreal Cognitive Assessment 21/30 and case 8, MMSE 23/30) to a diagnosis of dementia (case 5).

Response to levodopa in cases with parkinsonian phenotype was poor to moderate and proved particularly ineffective in patients with parkinsonism associated with supranuclear gaze palsy. Case 1 with confirmed DAT scan abnormality had some modest benefit from levodopa in the first year of treatment. However, the response to treatment was short lived and faded in the next 2 years of disease.

Neuroimaging spectrum {#s2-3}
---------------------

All patients showed extensive brain calcifications regardless of disease duration. Basal ganglia (putamen, internal globus pallidus, and caudate nucleus) were involved in all cases, whereas cerebellar hemispheres (folia and dentate nuclei) were involved in 75% of cases. Half of the cases also showed calcification of subcortical white matter. Extensive central pontine calcification was present in 3 cases. Cerebral cortical atrophy was observed in 37% of cases ([figure 2A](#F2){ref-type="fig"}).

![Neuroimaging spectrum in *MYORG* cases\
(A) Neuroimaging spectrum in *MYORG* cases. Cases 5 (A.a-A.c), 7 (A.d-A.f), and 8 (A.g-A.i) showed similar calcification pattern distribution with extensive involvement of cerebellar dentate nuclei and hemispheres, basal ganglia, thalami, and subcortical white matter; a characteristic central pontine calcification (red arrow) is present in all cases; frontotemporal and cerebellar atrophy was present in case 7; case 6: calcification of the internal globus pallidus, subcortical white matter, and dentate nuclei, with minimal involvement of thalami bilaterally. Severe frontotemporal and cerebellar atrophy is also detectable. (B) *MYORG* clinical spectrum correlates with *MYORG* gene expression in different brain areas. *MYORG* gene expression in different brain areas in adult pathologically normal human brains.^25^ *MYORG* is expressed in all 10 brain regions with highest expression detected in the putamen. CRBL = cerebellum; FCTX = frontal cortex; HIPP = hippocampus; MEDU = medulla; OCTX = occipital cortex; PUTM = putamen; SNIG = substantia nigra; TCTX = temporal cortex; THAL = thalamus; WHMT = white matter.](NG2019011999f2){#F2}

Discussion {#s3}
==========

In this study, we screened *MYORG* mutations in 86 cases from 60 unrelated, autosomal recessive PFBC families. We identified 7 new families of different ethnic backgrounds with disease-causing *MYORG* variants. Biallelic *MYORG* mutations were associated with PFBCs in 11.6% of families from our cohort. We identified 12 distinct mutations, suggesting that recurrent *MYORG* mutations are infrequent. Most of the initial reported cases came from consanguineous families.^[@R5],[@R6]^ Here, we present a cohort largely lacking in known consanguinity, with the majority of mutations inherited in the compound heterozygous state.

Our data suggest that the majority of cases have a disease onset in late adulthood with a combination of dysarthria, ataxia, parkinsonism, and cognitive decline consistent with the phenotypes previously reported in *MYORG* mutations^[@R5],[@R6],[@R16][@R17][@R19]^ and other autosomal dominant PFBC-causing genes.^[@R20]^ However, parkinsonism with supranuclear gaze palsy was frequently observed (37.8% of cases) in our cohort and has not been previously described in *MYORG* mutation carriers. Therefore, this further extends the phenotypic spectrum of *MYORG*-related disease. Of interest, central pontine calcification was present in over 1/3 of cases, which seems to be a radiologic diagnostic clue for *MYORG* mutation carriers, as this anatomic region is typically not affected in other genetic PFBC cases.^[@R6]^ As physiologic brain calcifications in this age group are reported in up to 20%,^[@R21],[@R22]^ an association of calcifications, supranuclear gaze palsy, and parkinsonism with atypical features such as ataxia or rapid cognitive decline should prompt physicians to test for *MYORG* mutations in this subgroup of patients. We show that next-generation sequencing can contribute to the diagnosis of late-onset, mildly affected or asymptomatic cases, therefore providing a more comprehensive understanding of the genetic architecture of brain calcifications.

The exact mechanism leading to disease in *MYORG* mutations is still unknown. On a cellular level, the gene is expressed in astrocytes localized to the endoplasmic reticulum^[@R5]^ and playing a role as glycosyl hydrolase.^[@R23]^ Although gene expression (Genotype-Tissue Expression^[@R24]^) is reported highest in the basal ganglia (nucleus accumbens and caudate) after the skeletal muscle, gene expression data in BRAINEAC^[@R25]^ suggest that the putamen and the thalamus express the most *MYORG* messenger RNA followed by the medulla and the substantia nigra ([figure 2B](#F2){ref-type="fig"}). These areas are mirrored in the clinical phenotype and calcification distribution on neuroimaging assessment in our cohort. Calcifications localized in the basal ganglia structures (100%), followed by the cerebellum in 75% of our cases, subcortical white matter (50%), and the thalamus (50%).

The phenotype observed in individuals with biallelic deleterious *MYORG* variants suggests a high variability among and within families with a disease severity ranging from insidious, incidental findings to severe, rapidly progressing disease course. Asymptomatic cases with biallelic *MYORG* mutations^[@R5]^ and heterozygous mutation carriers with punctate calcifications on the brain CT have been reported^[@R5],[@R6],[@R16]^). Our data together with previous reports suggest a dose-dependent phenotype based on the effect of mutations on the enzymatic activity of MYORG; however, no study has evaluated the enzymatic activity in *MYORG* mutations.

We show that biallelic *MYORG* mutations represent a significant proportion of PFBC cases without mutations in other known disease-causing genes. Here, we reported 12 distinct *MYORG* variants associated with brain calcifications and extended the phenotypic spectrum of this disease including atypical parkinsonism with pontine calcification. We recommend screening *MYORG* mutations in all patients with primary brain calcifications and autosomal recessive or negative family history.
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